New Biotech Firm Sets Up Shop In Gardner
A Gardner firm and a cancer research center in Canada have launched a new biotechnology company that hopes to create about a dozen jobs over the next three years.
The formation of the company, Excipio Technologies, was announced this morning in Gardner, home to one of the partners in the joint venture, New England Peptide (NEP) of Gardner. The other partner is the Atlantic Cancer Research Institute (ACRI), based in Moncton, New Brunswick.
Excipio’s mission will be to bring to market a synthetic peptide that can extract diagnostic information on potentially cancer-diseased cells through a quick test of a patient’s blood, urine or saliva, rather than forcing the patient go through something more invasive such as a biopsy.
The peptide, called Vn96, has been jointly developed by NEP and ACRI, which, in 2009, formed a partnership to develop cancer-related peptides.
NEP, founded in 1998, has more than 1,000 clients in 80 countries in the biotech and pharmaceutical industries as well as in academia.. “In our 15-year history, we have collaborated with scientists on a variety of projects, and Vn96 is by far the most promising,” said Sam Massoni, CEO of NEP. “To think we can enrich and purify incredible amounts of biological information in less than an hour is amazing. Now we need Excipio to discover what we can use that information for.”
Massoni said all Vn96 manufacturing will be conducted in Gardner. He added that NEP is also expanding and has made an offer to purchase a building in the city that will house Excipio. The company’s business plan calls for the creation of five to 15 jobs split between Gardner and New Brunswick, he said.
WBJ Web Partners
Most Recent
Most Recent
0 Comments